Nycomed Gmbh

Byk Gulden Lomberg Chemische Fabrik Gmbh

Altana Pharma Ag

Takeda Gmbh

Astrazeneca Ab

Rudolf Linder

Rango Dietrich

Hartmut Ney

Klaus-Dieter Beller

Uwe Kruger

Bernhard Keppler

Heimo Keller

Rita Lippert

Christina Bolle

Rüdiger Koenen

An aqueous pharmaceutical preparation for administration of a slightly soluble PDE4 inhibitor is described.

Aqueous pharmaceutical preparation comprising roflumilast

Lyophilized pantoprazole preparations which are obtainable by freeze-drying of an aqueous solution of pantoprazole, ethylenediamine tetraacetic acid and/or a suitable salt thereof, and sodium hydroxide and/or sodium carbonate are disclosed. The preparations have advantageous properties when reconstituted for injection.

Freeze-dried pantoprazole preparation and pantoprazole injection

The present invention relates to the field of pharmaceutical technology and describes a pharmaceutical preparation in the form of a paste comprising an acid-labile active ingredient, in particular an acid-labile proton pump inhibitor. The invention also relates to processes for producing the paste. The paste is particularly suitable for administering acid-labile active ingredients to animals or to people who have difficulty taking solid dosage forms such as tablets or capsules.

Pharmaceutical preparation in the form of a paste comprising an acid-labile active ingredient

The present invention relates to the field of pharmaceutical technology and describes a novel advantageous preparation for an active ingredient. The novel preparation is suitable for producing a large number of pharmaceutical dosage forms. In the new preparation, an active ingredient is present essentially uniformly dispersed in an excipient matrix composed of one or more excipients selected from the group of fatty alcohols, triglycerides, partial triglycerides and fatty acid esters.

Pharmaceutical preparation comprising an active dispersed on a matrix

Novel administration forms and preparations for acid-labile active compounds are described. The novel administration forms contain individual active compound units, the active compound being present in the active compound units in a matrix made of a mixture comprising at least one fatty alcohol and at least one solid paraffin, in a matrix made of a mixture of a triglyceride and at least one solid paraffin or in a matrix made of a mixture comprising at least one fatty acid ester and at least one solid paraffin. In particular, the active compound units are microspheres which can be produced by prilling.

Preparation and administration form comprising an acid-labile active compound

Novel administration forms and preparation for acid-labile active compounds are described. The novel administration forms contain individual active compound units, the active compound being present in the active compound units in a matrix made of a mixture comprising at least one fatty alcohol and at least one solid paraffin, in a matrix made of a mixture of a triglyceride and at least one solid paraffin or in a matrix made of a mixture comprising at least one fatty acid ester and at least one solid paraffin. In particular, the active compound units are microspheres which can be produced by prilling.

The present invention relates to the field of pharmaceutical technology and describes a novel pharmaceutical preparation in the form of a suspension comprising an acid-labile active ingredient, in particular an acid-labile proton pump inhibitor. The invention also relates to processes for producing the suspension. The suspension is particularly suitable for administering acid-labile active ingredients to people who have difficulty taking solid dosage forms such as tablets or capsules.

Pharmaceutical preparation in the form of a suspension comprising an acid-labile active ingredient

The present invention relates to the field of pharmaceutical technology and describes a novel advantageous preparation for an active ingredient. The novel preparation is suitable for producing a large number of pharmaceutical dosage forms. In the new preparation an active ingredient is present essentially uniformly dispersed in an excipient matrix composed of one or more excipients selected from the group of fatty alcohol, triglyceride, partial glyceride and fatty acid ester.

A rapidly disintegrating tablet for oral administration of acid-labile active ingredients is described. The rapidly disintegrating tablet for oral administration of an acid-labile active ingredient comprises a plurality of individual active ingredient units together with pharmaceutical excipients, where the acid-labile active ingredient is present in the individual active ingredient units in a matrix composed of a mixture comprising at least one solid paraffin and one or more substances from the group of fatty alcohol, triglyceride and fatty acid ester, and where excipients which, on oral intake of the tablet, bring about rapid disintegration of the tablet are present.

Rapidly disintegrating tablet comprising an acid-labile active ingredient

Novel administration forms for acid-labile active compounds are described. The novel administration forms have no enteric layers and are suitable for oral administration.

Administration form comprising an acid-labile active compound

Acid-labile active compounds are prepared in suppository form, particularly for rectal administration.

Suppository composition which is a spray-dried suspension of an acid-labile proton pump inhibitor in a solvent solution of a sterol and polymer

An administration form for acid-labile active compounds are described. The administration forms have no enteric layers and are suitable for oral administration.

Growing community of inventors

Constance, Germany

Rudolf Linder